Skip Navigation LinksHome > July 2008 - Volume 27 - Issue 7 > Respiratory Syncytial Virus Prophylaxis in a High-Risk Popul...
Pediatric Infectious Disease Journal:
doi: 10.1097/INF.0b013e3181691753
Brief Reports

Respiratory Syncytial Virus Prophylaxis in a High-Risk Population in Argentina: A Cost-Effectiveness Analysis

Rodríguez, Susana P. MD*; Fariña, Diana MD*; Bauer, Gabriela MD†

Collapse Box

Abstract

Palivizumab has proved effective in reducing hospitalization rates because of respiratory syncytial virus in vulnerable groups. In Argentina its administration is not universal because of high costs. We made a cohort study and enrolled 159 children who met the American Academy of Pediatrics recommendations but did not receive palivizumab; 26% required hospitalization for respiratory syncytial virus infection. Siblings and bronchopulmonary dysplasia were associated with higher hospitalization. For high-risk patients, one averted hospitalization was associated with costs of U.S. dollars (USD)13, 198 [number needed to treat (NNT): 4.5].

© 2008 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.